Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer

NCT02984683 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02984683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02984683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
March 23, 2017
Completion date
September 7, 2018
Enrollment
23 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer